Senseonics公司近日迎来重大突破——首批商业患者已开始联合使用其革命性的Eversense 365长效动态血糖监测仪与Twiist™自动胰岛素输送系统。这一里程碑标志着糖尿病管理技术迈入全新阶段。
Eversense 365作为目前唯一获批可连续佩戴365天的植入式CGM设备，与Twiist AID系统的无缝集成，实现了血糖监测与胰岛素调节的闭环自动化。患者将享受前所未有的自由：无需每日指尖采血，系统能主动预测血糖波动并智能调整胰岛素输注量。
此次商业化应用验证了长期CGM与自动化疗法结合的可能性。医疗界关注的是，这种组合能否在降低糖化血红蛋白水平的同时，最大限度减少夜间低血糖事件。临床数据表明，双系统协同作用可提升血糖达标时间达72%。
对于依赖胰岛素治疗的糖尿病患者而言，这项技术融合意味着生活质量的飞跃。365天持续监测配合自适应算法，不仅减轻疾病管理负担，更重新定义了精准医疗的边界。行业观察家指出，这种长期植入式设备与AI驱动疗法的结合，可能成为糖尿病数字化管理的黄金标准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.